In an independent preclinical study of subcutaneous tumors, vaccination combined with PD-(L)1 and CTLA-4 inhibition led to improved tumor rejection and mouse survival, when compared to dual- and mono-therapeutic treatment.83 Here, CTLA4 is linked to neoplasm.